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Sequential phase II Southwest Oncology Group studies (S0112
and S0301) of daunorubicin and cytarabine by continuous
infusion, without and with ciclosporin, in older patients with
previously untreated acute myeloid leukaemia
The median age of patients with acute myeloid leukaemia
(AML) exceeds 60 years, and despite advances in therapy for
younger patients, older patients continue to have poor
outcomes with little improvement over time. Induction
outcomes in older patients are often complicated by more
frequent co-morbidities, and by fundamental differences in
disease biology (Leith et al, 1997, 1999; Godwin et al, 1998;
Goldstone et al, 2001; Anderson et al, 2002; Appelbaum et al,
2006; Farag et al, 2006; Wilson et al, 2006; van den Heuvel-
Eibrink et al, 2007; van der Holt et al, 2007). These biological
differences include, among others, an increased frequency of
expression of P-glycoprotein (Pgp) and other drug efflux
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Summary
Attempts to overcome multi-drug resistance in acute myeloid leukaemia
(AML) have been limited by toxicities. To investigate the effect of reducing
peak drug levels, we performed sequential phase II studies using continuous
infusion daunorubicin and cytarabine without (AD) and then with
ciclosporin (ADC) in older patients with AML. Untreated patients (age
56+ years) received daunorubicin (45 mg/m2 per day for 3 d) and cytarabine
(200 mg/m2 per day for 7 d), both by continuous infusion, without (S0112,
60 patients) and then with (S0301, 50 patients) the addition of ciclosporin.
Complete response (CR) rates were 38% on S0112 and 44% on S0301. Fatal
induction toxicities occurred in 17% and 12% respectively, arising primarily
from infection and haemorrhage. Median overall and relapse-free survival
was 7 and 8 months for AD respectively, and 6 and 14 months for ADC.
Patients with phenotypic or functional P-glycoprotein had somewhat higher
CR rates with ADC than AD, although confidence intervals overlapped. In
these sequential trials, continuous infusion AD produced CR rates
comparable to those with bolus daunorubicin. The addition of ciclosporin
did not cause undue toxicities, produced a similar CR rate, and possibly
improved relapse-free survival. Further correlate analyses did not identify a
subpopulation specifically benefitting from the addition of ciclosporin.
Keywords: acute myeloid leukaemia, P-glycoprotein, multi-drug resistance,
ciclosporin, chemoresistance.
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proteins that share homology with the ATP-Binding Cassette
(ABC) transporters (Ross et al, 1993, 1994; van den Heuvel-
Eibrink et al, 2001, 2002; Mahadevan & List, 2004;
Schilthuizen et al, 2007). Compounds, such as ciclosporin
and its derivative PSC-833, as well as unrelated compounds
such as zosuquidar have been investigated in younger and older
patients with AML in attempts to overcome resistance and
improve treatment outcomes (Solary et al, 1996; Advani et al,
1999; Lee et al, 1999; Tallman et al, 1999; Chauncey et al, 2000;
List et al, 2001, 2002; Liu Yin et al, 2001; Baer et al, 2002; Solary
et al, 2003; van der Holt et al, 2005; Greenberg et al, 2004;
Burnett et al, 2009; Becton et al, 2006; Lancet et al, 2009). To
date, however, none of these strategies have been consistently
successful in improving outcome in younger or older patients,
and many trials have been complicated by increased chemo-
therapy-related toxicities owing to higher blood levels of
antineoplastics, such as anthracyclines and etoposide, when
administered with these Pgp-modulating agents.
Based on the hypothesis that anthracycline-related toxicity in
these regimens may be ascribed to higher peak drug concen-
trations rather than total drug exposure, we previously
conducted a trial in patients with recurrent or untreated
secondary AML testing the effect of ciclosporin with continuous
infusion daunorubicin and high-dose cytarabine (List et al,
2001). In that prospective randomized trial (S9126), the
addition of ciclosporin did not significantly improve the
complete response rate, but the incidence of induction failure
due to resistant disease (RD) was significantly reduced, and
both relapse-free and overall survivals were significantly pro-
longed. The benefit of ciclosporin was greatest in patients whose
blasts expressed a multi-drug resistant (MDR) phenotype.
Considering the high frequency of Pgp expression in older
AML patients, we performed sequential phase II feasibility
studies to assess the tolerance of infusional daunorubicin and
cytarabine administration in older patients with AML, either
alone (study S0112) or with the addition of ciclosporin (study
S0301). The second study would proceed only if continuous
infusion daunorubicin had no untoward impact on toxicity or
efficacy. The results of S0112 were, within the limits of study
size, similar to those in previous Southwest Oncology Group
(SWOG) trials in similar patients using bolus daunorubicin,
allowing S0301 to proceed. The addition of ciclosporin to the
infusional induction regimen was poorly tolerated in the aged
and those patients with very poor performance status. After
exclusion of those patients from study eligibility, the addition
of ciclosporin did not appear to increase toxicities.
Patients, materials and methods
Eligibility
Patients 56 years of age or older with a morphologically
confirmed diagnosis of AML, except for acute promyelocytic
leukaemia (M3), were eligible (Cheson et al, 2003). Diagnosis
of AML was by French-American-British (FAB) criteria, i.e.
required ‡30% marrow blasts (‡20% if the peripheral blast
percentage was ‡30%). Patients with blast crisis of chronic
myeloid leukaemia were excluded. Prior systemic chemother-
apy for acute leukaemia was not permitted, although treat-
ment for hyperleucocytosis with hydroxycarbamide, or
intrathecal therapy for suspected or proven central nervous
system involvement was allowed. Patients with secondary
AML, defined as AML arising after a morphological diagnosis
as myelodysplasia (MDS) (Cheson et al, 2003) or AML arising
after prior chemotherapy or radiotherapy, were not excluded.
Prior treatment for MDS with cytarabine (£100 mg/m2) or
azacitidine administered more than 30 d before administration
was allowed. Patients were initially required to have perfor-
mance status (PS) of 0–3 by SWOG criteria. However, in
S0301, the permissible range of PS was modified after the
initial 14 patients as described below. The modified criteria
permitted PS 0–3 for patients aged £60 years, 0–2 for age
61–70 years and 0–1 for age ‡71 years. Adequate solid organ
function was required, as defined by (i) serum bilirubin
£2 times institutional upper limits of normal (IULN); (ii)
aspartate transaminase and/or alanine transaminase £4 ·
IULN; (iii) serum creatinine £1Æ5 · IULN and/or creatinine
clearance ‡0Æ67 ml/s; (iv) ejection fraction ‡50% as measured
by either multigated cardiac blood pool (MUGA) scan or
echocardiography; and (v) absence of unstable cardiac
arrhythmia or unstable angina. Informed consent in accor-
dance with local institutional guidelines and federal regulations
was required of all patients.
Treatment plans
For S0112, patients received cytarabine 200 mg/m2 daily by
24-h continuous infusion on days 1–7 and daunorubicin
45 mg/m2, also as 24-h continuous infusion on days 1–3. For
S0301, ciclosporin A was added as a loading dose of 6 mg/kg
over 2 h followed by 16 mg/kg per day by continuous infusion
for 3 d. A bone marrow aspirate and biopsy was obtained on
day 14 and if the marrow blast percentage was more than or
equal to 5%, a second cycle of induction of identical
chemotherapy was administered upon the earliest recovery of
marrow cellularity to more than 20%. Once the marrow blast
percentage of <5% was documented, patients received either
granulocyte colony-stimulating factor (G-CSF) or granulocyte-
macrophage colony-stimulating factor (GM-CSF), adminis-
tered intravenously once daily until the absolute neutrophil
count (ANC) reached 1Æ5 · 109/l (Godwin et al, 1998). The
dose and drugs administered for cycle two were the same as
cycle one except daunorubicin was reduced by 50% for serum
bilirubin between 2–4 · IULN, or discontinued for higher
serum bilirubin concentrations.
Supportive care
All patients received antimicrobial prophylaxis as follows: (i)
ciprofloxacin 500 mg orally or 200 mg intravenously twice
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daily until administration of broad spectrum antibiotics for
febrile neutropenia; (ii) fluconazole, to begin 48 h after
completion of chemotherapy at 200 mg orally or intravenously
daily or until administration of broad spectrum antifungal
therapy and (iii) among patients who were seropositive for
herpes simplex virus, acyclovir 800 mg orally or 250 mg/m2
intravenously twice daily, to begin 48 h after completion of
chemotherapy. If patients developed febrile neutropenia,
ciprofloxacin was discontinued and parenteral broad-spectrum
antipseudomonal antibiotic coverage was instituted. Antibio-
tics were continued until the ANC was over 0Æ5 · 109/l, and
clinical signs of infection resolved. Guidelines for transfusion
support included prophylactic platelet transfusion at a thresh-
old of 10Æ0 · 109/l in asymptomatic patients and red cell
transfusion at a haemoglobin threshold of 80 g/l. Early
institution of hyperalimentation was recommended for
patients with poor oral intake.
Post-remission therapy
Patients on either study who achieved a complete response
(CR) after one or two cycles of induction chemotherapy were
registered to receive two cycles of post-remission therapy. For
S0112, this consisted of daunorubicin (45 mg/m2) intra-
venously as 24-h continuous intravenous infusion on days 1
and 2, and cytarabine (200 mg/m2) daily as 24-h continuous
infusion on days 1–5. On S0301, an identical regimen was
used with the addition of ciclosporin at a loading dose of
6 mg/kg over 2 h, followed by 16 mg/kg per day by contin-
uous intravenous infusion on days 1–2. Performance status
0–2 by SWOG criteria and serum bilirubin less than or equal
to twice the IULN were required for post-remission therapy,
as was a MUGA scan demonstrating an ejection fraction more
than or equal to 45%, for patients with cardiac toxicity after
induction therapy. Use of G-CSF or GM-CSF with post-
remission therapy was left to the discretion of the treating
physician.
Definitions of outcomes
Response criteria were adapted from National Cancer
Institute (NCI)-sponsored workshop guidelines (Cheson
et al, 1990). CR required the following for ‡28 d: marrow
with >20% cellularity, <5% blasts and no Auer rods;
peripheral blood with neutrophil count >1Æ5 · 109/l, platelet
count >100 · 109/l, and no blasts; and absence of extra-
medullary disease. Responses meeting CR criteria but
without evidence of ‡28-d duration were designated as
‘unconfirmed CR.’ Patients who failed to achieve CR after
induction therapy were classified according to type of failure:
resistant disease (RD); death during aplasia; or indeter-
minate, defined as death <7 d after completion of induction
therapy or with no persistent leukaemia in the peripheral
blood, but no post-induction marrow examination (Cheson
et al, 2003). Overall survival (OS) was measured from the
date of registration until death from any cause, with
observation censored at the date of last contact for patients
last known to be alive. Relapse-free survival (RFS) was
measured from the date of CR until relapse or death from
any cause, with observation censored at the date of last
contact for patients last known to be alive without report of
relapse. Toxicities were defined and graded according to the
NCI Common Toxicity Criteria version 2.0 (http://ctep.
cancer.gov/protocolDevelopment/electronic_applications/docs/
ctcv20_4-30-992.pdf) for S0112 and Common Terminology
Criteria for Adverse Events version 3.0 (http://ctep.cancer.
gov/protocolDevelopment/electronic_applications/docs/ctcaev3.
pdf) for S0301.
Laboratory and cytogenetic data
Multi-drug resistance (MDR)-1 expression by the leukaemic
blasts was measured using MRK-16 and three colour flow
cytometric assays for blasts co-staining with CD34 (hemato-
poietic stem/progenitor cell antigen) and CD33 (panmyeloid
antigen) as previously described (Leith et al, 1999). To assess
ciclosporin-inhibited functional drug efflux of the leukaemia
blasts, two fluorescent dyes, diethyloxacarbocyanine iodide
[Di(OC)2] and rhodamine 123 (Rh123), were measured with
and without exposure to ciclosporin (CSA) in a single-colour
flow cytometric assay as described in previous reports (Leith
et al, 1999). MRK-16 expression and CSA-inhibited Di(OC)2
and Rh123 efflux were measured as continuous values using
the Kolmogorov-Smirnov statistic, denoted D (Young, 1977).
Cytogenetic studies were performed at previously approved
laboratories and centrally reviewed by the SWOG Cytogene-
tics Committee. Cytogenetic abnormalities were grouped
according to published criteria adopted by SWOG as
favourable, intermediate, unfavourable, or unknown (Slovak
et al, 2000).
Statistical considerations
Each trial was conducted in two steps to permit termination
if early results proved unfavourable. In S0112, if ‡9 of the first
30 patients achieved CR, 25 more would be enrolled; if ‡23 of
the 55 achieved CR, results would be considered favourable.
This design had critical (a) level 4% if the true CR rate with
daunorubicin and cytarabine (AD) is 30%, and power 91% if
the true CR rate is 50%. S0301 tested both response and the
following indicator toxicity: any Grade 4+ non-haematological
toxicity except (i) hyperbilirubinemia or (ii) mucositis
assigned Grade 4 due solely to ulceration (not requiring
enteral/parenteral nutrition or prophylactic intubation).
Initially S0301 would accrue 25 patients; if <7 achieved CR
or >10 experienced indicator toxicity, the trial would end,
otherwise another 25 would be enrolled. Results would be
favourable for ADC (AD + ciclosporin) if ‡16 of 50 achieved
CR and <18 experienced indicator toxicity. S0301 had a level
<5% if the true CR rate is £25% or the true risk of indicator
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toxicity is ‡45%, and power ‡89% if the true CR rate is ‡45%
and the true risk of indicator toxicity is £25%. Neither trial was
stopped early, although the S0301 eligibility criteria were
modified as described below. Logistic regression analysis
and Fisher’s exact test (for CR and RD) and proportional
hazards regression (for OS and RFS) were used to test the
effects on treatment outcomes of patient and disease charac-
teristics including MDR. Distributions of OS and RFS were
estimated by the method of Kaplan and Meier (1958).
Confidence intervals (CIs) were calculated at the 95% confi-
dence level. Results are based on data available as of March 23,
2009.
Results
Patient accrual and characteristics
Study S0112. A total of 71 patients from 24 institutions were
enrolled on study S0112 between August 2001 and April 2003.
Ten were ineligible because of non-AML diagnosis (N = 8),
PS = 4 (N = 1), or prestudy MUGA <50% (N = 1). An
additional patient died before treatment and was excluded
from the analysis. Demographic and disease characteristics for
the 60 included patients are summarized in Table I. Sixteen
patients (27%) had AML secondary to prior MDS (N = 14) or
Table I. Demographic and disease characteris-





criteria (N = 14)
S0301: revised
eligibility
criteria (N = 50)
Age (years) 68 (56, 85) 69 (57, 80) 65 (56, 81)
Sex (Males) 29 (48%) 11 (79%) 30 (60%)
Performance Status 0 20 (33%) 2 (14%) 18 (36%)
1 25 (42%) 7 (50%) 28 (56%)
2 11 (18%) 2 (14%) 4 (8%)
3 4 (7%) 3 (21%) 0
Race White 57 (95%) 14 (100%) 43 (86%)
Black 2 (3%) 0 3 (6%)
Asian 1 (2%) 0 0
Unknown 0 0 4 (8%)
AML onset De novo 44 (73%) 10 (71%) 42 (84%)
MDS-related 14 (23%) 4 (29%) 7 (14%)
Treatment
related
2 (3%) 0 0
Unknown 0 0 1 (2%)
Laboratory values*
WBC count(1Æ0 · 109/l) 8Æ5 (0Æ6, 152Æ4) 8Æ4 (0Æ7, 91Æ6) 10Æ4 (0Æ6, 172Æ6)
Platelet count (1Æ0 · 109/l) 57 (5, 438) 47 (12, 159) 57 (13, 643)
Neutrophils (%) 16 (0, 75) 7 (0, 31) 12 (0, 67)
Haemoglobin (g/l) 94 (56, 146) 90 (75, 106) 92 (57, 124)
Blasts(%)–blood 16 (0, 91) 35 (0, 88) 23 (0, 98)
Blasts(%)–marrow 51 (13, 97) 54 (23, 90) 62 (17,98)
FAB classification M0 4 (7%) 0 4 (8%)
M1 15 (25%) 5 (36%) 10 (20%)
M2 15 (25%) 4 (29%) 10 (20%)
M4 14 (23%) 3 (21%) 15 (30%)
M4eos 1 (2%) 0 2 (4%)
M5 8 (13%) 2 (14%) 6 (12%)
M6 2 (3%) 0 2 (4%)
M7 1 (2%) 0 1 (2%)
Cytogenetic Risk
classification
Evaluable 51 11 31
Unfavourable§ 19 (37%) 2 (18%) 12 (39%)
Intermediate§ 29 (57%) 7 (64%) 16 (52%)
– Normal§ 25 (49%) 4 (36%) 11 (35%)
Favourable§ 3 (6%) 2 (18%) 3 (10%)
AML, acute myeloid leukaemia; WBC, white blood cell; FAB, French-American-British.
*Median (min, max).
Not reported for one patient.
Not reported for two patients.
§Percentages based on number with evaluable cytogenetics.
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prior cytotoxic chemotherapy or chemoradiotherapy (N = 2).
Pre-treatment cytogenetic results were not available for 9
(15%) eligible patients, either because specimens were not
submitted to approved laboratories (N = 2) or evaluable
studies were not obtained (N = 7). Among 51 patients with
cytogenetic data, 37% had unfavourable karyotypes. MRK16
expression was detected in 64% of patients, and CSA-inhibited
efflux of Di(OC)2 and Rh123 occurred in 73% and 72%
respectively, of patients tested for MDR-1 expression or
function (Table II).
Study S0301. Study S0301 was activated in October 2003, but
was temporarily closed in March 2004 after accruing 14
patients at six institutions due to concern about possible
excessive toxicity and early mortality, particularly among older
patients with poor performance status. At the time, six patients
had died within 30 d of study entry, an additional patient had
grade 4 non-haematological toxicities, and median survival
was only 2 months, though for the 6 (43%) who achieved CR,
the median RFS was 8 months. Because of these results, study
S0301 was amended to exclude patients of age 61–70 with PS 3,
and patients of age 70+ with PS 2–3. The two-stage design was
reinitiated after this modification, so that 25–50 patients
meeting the amended eligibility criteria would be enrolled. The
results for study S0301 presented below focus primarily on
patients registered after the eligibility criteria modification,
although results for the first 14 patients are included in some
summaries for completeness. After the modification, 55
patients were accrued between August 2004 and December
2006, at 16 institutions. Three patients were ineligible because
of non-AML diagnosis (N = 2), or presence of concomitant
malignancy (N = 1) at the time of registration. Two additional
patients who did not receive study treatment are excluded
from the analysis. Among the 50 eligible patients, 42 (84%)
had de novo disease, 7 (14%) had prior MDS and 1 (2%) had
unknown prior disease status. Pre-treatment cytogenetic
results were not available for 19 (40%) eligible patients
because specimens were not submitted to approved
laboratories (N = 7) or evaluable studies were not obtained
(N = 12). Among 31 patients with cytogenetic data, 39% had
unfavourable karyotypes. MRK16 expression was found in
50% of patients, and CSA-inhibited efflux of Di(OC)2 and
Rh123 was seen in 44% and 36% respectively (Table II).
Response to induction therapy
Study S0112. As shown in Table III, 23 (38%) of the 60
patients on S0112 achieved CR (CI 26–52%). Nineteen patients
(32%) achieved CR after a single course of induction therapy.
An additional 20 patients received a second course of identical
induction therapy, and four (20%) of these achieved CR.
Nineteen patients (32%, CI 20–45%) had RD following one
(N = 7) or two (N = 12) courses of induction therapy.
Responses of nine patients (15%) were indeterminate due to
death within 7 d of completing induction therapy or during
subsequent aplasia, and the response of nine others was not
adequately assessed. Twenty of the first 55 patients achieved
CR, fewer than the 23 required for the primary test of
effectiveness. Fifty-six (93%) patients experienced non-
haematological toxicities of grade 3 or higher. These
included 10 (17%) with fatal induction toxicities, most
commonly infection (N = 6), haemorrhage (N = 4) and/or
cardiac toxicity (N = 2) and 12 others (20%) with grade 4
non-haematological toxicities.
Study S0301. Twenty-two (44%) of the 50 patients on S0301
achieved CR (CI 30–59%), all after a single cycle of induction
chemotherapy (Table III). Seven patients received a second
course of induction, but none achieved CR. Thirteen patients
(26%) had RD (CI 15–40%) following one (N = 10) or two
(N = 3) courses of induction therapy. Responses of six patients
(12%) were indeterminate due to death within 7 d of
completing induction therapy or during subsequent aplasia,
and responses of nine others were not adequately assessed.
Table II. MDR1 Expression and functional









MRK16* Negative 13 (26%) 1 (7%) 21 (42%)
Weak positive 5 (10%) 4 (29%) 4 (8%)
Positive 32 (64%) 9 (64%) 25 (50%)
Di(OC)2 efflux* Negative 9 (24%) 1 (10%) 17 (47%)
Weak positive 1 (3%) 1 (10%) 3 (8%)
Positive 27 (73%) 8 (80%) 16 (44%)
Not done 13 4 14
Rh123 efflux* Negative 8 (25%) 2 (22%) 20 (56%)
Weak positive 1 (3%) 0 (0%) 3 (8%)
Positive 23 (72%) 7 (78%) 13 (36%)
Not done 18 5 14
*Negative: Kolmogorov-Smirnov D < 0Æ15; Weak positive: 0Æ15 £ D < 0Æ20; Positive: D ‡ 0Æ2.
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Forty patients (80%) had non-haematological toxicities of
grade 3 or higher. Six patients (12%) suffered fatal induction
toxicities including infection (N = 3), pulmonary
haemorrhage (N = 2) and asystole (N = 1) and eight others
(16%) experienced grade 4 non-haematological toxicities.
Consequently, the ADC regimen met both the response and
toxicity criteria defined for study S0301.
Post-remission therapy
Study S0112. On S0112, 3 patients who achieved a CR were
not registered for consolidation. Thirty-one patients were
registered for consolidation, though 11 were ineligible and
excluded from the analysis. Of the 20 evaluable patients on
S0112 who were registered and received protocol post-
remission therapy, 19 completed the two cycles of
consolidation therapy specified in the protocol. There were
no fatal toxicities, and one patient experienced grade 4 non-
haematological toxicities including lung infection, acute
respiratory distress syndrome, central nervous system
haemorrhage, confusion, anxiety and hepatotoxicity.
Study S0301. On S0301, 19 patients were registered for
consolidation. One patient was excluded due to incomplete
blood count recovery following induction therapy. Of the 18
patients, there was one fatality from sepsis, and another patient
experienced grade 4 non-haematological toxicity (high
glucose). Three patients did not receive the second cycle of
protocol-specified consolidation therapy.
Overall and relapse-free survival
Study S0112. Of the 60 evaluable patients on S0112, 57 have
died. The remaining patients were last known to be alive 73, 75
and 81 months after entry into the study. The median OS was
7 months (CI 3–10 months), and the estimated probability of
survival was 33% (CI 21–45%) at 1 year and 15% (CI 6–24%)
at 2 years (Fig 1).
Of the 23 patients who achieved complete remission on
S0112, 19 have relapsed and one other died without report of
disease status. The estimated median RFS was 8 months (CI
5–11 months), and the estimated probability of RFS was 35%
(CI 15–54%) at 1 year, and 22% (CI 5–39%) at 2 years (Fig 2).
Study S0301. Of the 50 evaluable patients on S0301, 40 have
died, and the remaining 10 patients were last known to be alive
between 22 and 34 months (median 27 months). The
estimated median OS was 6 months (CI 2–11 months), and
the estimated probability of survival was 38% (CI 24–51%) at
1 year, and 28% (CI 16–40%) at 2 years (Fig 3).
Of the 22 patients who achieved CR on S0301, eleven have
relapsed and four others have died without report of relapse.










Complete response Confirmed 6 (10%) 4 (29%) 10 (20%)
Unconfirmed 17 (28%) 2 (14%) 12 (24%)
Total 23 (38%) 6 (43%) 22 (44%)
Resistant disease 19 (32%) 2 (14%) 13 (26%)
Died during aplasia 5 (8%) 2 (14%) 2 (4%)
Died <7 d after 1st course 4 (7%) 3 (21%) 4 (8%)
Died without bone marrow exam 2 (3%) 1 (7%) 4 (8%)


































Fig 2. S0112 relapse-free survival.
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The estimated median RFS was 14 months (CI 7–19 months)
and the estimated probability of RFS was 55% (CI 34–75%) at
1 year and 36% (CI 16–56%) at 2 years (Fig 4).
Effect of MDR and other demographics on treatment
outcomes
Analyses of cytogenetics, phenotypic drug efflux, CD34
expression, white count, performance status and history of
prior antecedent myelodysplastic syndrome did not identify a
population of patients specifically benefitting from the addi-
tion of ciclosporin (Tables SI–SIII).
The impact of MDR phenotype on treatment outcome was
analysed separately for S0112 (without ciclosporin) and S0301
(with ciclosporin). In S0112, MDR as measured by Rh123
efflux was associated with a lower CR rate (P = 0Æ036), but
neither MRK16 expression nor Di(OC)2 efflux was statistically
significantly associated with remission rates (Table IV). RD as
a cause of induction failure tended to increase with CSA-
inhibited efflux of both Di(OC)2 (P = 0Æ48) and Rh123
(P = 0Æ54). None of the measures of MDR were significantly
associated with OS or RFS, a finding that is not unexpected
given the small number of remitting patients. In S0301, the CR
rate did not vary significantly according to any of the three
measures of MDR, although the RD rate tended to increase
with increasing Di(OC)2 efflux (P = 0Æ049). None of the other
associations of MDR phenotype and treatment outcome were
significant.
Discussion
In these sequential phase II studies, the administration of
daunorubicin by continuous infusion along with cytarabine
did not significantly alter the toxicity profile or the efficacy of
the standard ‘7 + 3’ regimen in older adults with newly
diagnosed AML. In contrast, the addition of ciclosporin to the
continuous infusion regimen increased toxicity in very old
patients with poor performance status. This finding is consis-
tent with earlier SWOG studies that have shown the interac-
tion of age and performance status in determining outcome
for this older AML population (Appelbaum et al, 2006). Once
this subgroup of patients was excluded from enrollment, the
toxicities in S0301 were not markedly different from those seen
in S0112. Although study S0112 did not meet its planned test
criterion for efficacy, the CR rate for patients on both studies
were consistent with past experience for older AML patients;
38% (CI 26–52%) with AD on S0112, and 44% (CI 30–59%)
with ADC on S0301.
These phase II studies were not designed to formally
compare the effectiveness of these two regimens. Nevertheless,
it is noteworthy that the addition of ciclosporin in S0301 did
not produce a markedly higher CR rate or lower RD rate than
seen in S0112, even though the S0301 patients had a better
overall performance status. Still, RFS appeared to be somewhat
longer in S0301 (with ciclosporin, 14 months) compared to
S0112 (without ciclosporin, 8 months). Nevertheless, this was
not a prospective randomized study and the confidence
intervals for RFS and OS overlap between studies. Such
comparisons must be interpreted cautiously in two sequential
trials. Indeed, after the eligibility criteria were revised for
S0301, restricting enrollment for older patients with poor
performance status, baseline patient characteristics became
slightly more favourable on S0301 than S0112. Nonetheless,
the possibility of improved remission maintenance with the
addition of ciclosporin cannot be excluded. Such an effect is
consistent with the outcome of the phase III randomized trial,
S9126 (List et al, 2001), where the addition of ciclosporin to a
regimen of continuous infusion daunorubicin plus high-dose
cytarabine did not improve complete response rates, but did
lead to a significantly lower rate of RD and prolonged RFS and
OS in younger patients with recurrent or secondary AML. The
current phase II studies suggest that ciclosporin as a modulator
of MDR in older patients may impact remission duration
rather than remission induction.
Various measures of the MDR phenotype were studied in
S0112 and S0301 with the hypothesis that their association
with outcome would be seen most clearly in S0112, but
attenuated in S0301 with the addition of ciclosporin. The
baseline assessment of phenotypic and functional Pgp


































Fig 4. S0301 revised eligibility: relapse-free survival.
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(Table II). Whether this difference was a chance occurrence or
the result of an unidentified change in methodology is
unknown. Although there were trends in association for
several measures of MDR with lack of CR and persistent
disease in S0112, these patterns were not strikingly altered by
the addition of ciclosporin in S0301 (Table IV). However,
because of the differences in baseline measures, the proportion
of patients not evaluable for MDR function in S0301 (28%),
and the limited number of complete responders, comparisons
of MDR expression and treatment responses between studies
are difficult.
Other studies have investigated Pgp-modulation in patients
with relapsed and refractory AML. In the UK Medical Research
Council (MRC) AML-R study, patients with relapsed or
refractory AML were randomized to ADE (cytarabine, dauno-
rubicin, etoposide) with and without ciclosporin at 5 mg/kg
per day (Liu Yin et al, 2001). There was no apparent benefit,
though the ciclosporin dosing was arguably inadequate for
reversing Pgp-mediated efflux (List et al, 2001; Mahadevan &
List, 2004; Qadir et al, 2005). A salient feature of many of the
Pgp-efflux inhibitors is their pharmacokinetic effects on other
cytotoxic drugs, such as anthracyclines and etoposide. This has
typically required dose-attenuation of cytotoxic drugs with the
goal of achieving equitoxic regimens with and without the
modifying agent. This strategy, in turn, creates a complex
interaction of cytotoxic drugs with a spectrum of toxicities and
risks underdosing of patients without pharmacokinetic
changes. Other Pgp-inhibitors, such as zosuquidar, show very
little pharmacodynamic effects on cytotoxic agents, although a
recent Eastern Cooperative Oncology Group (ECOG) study in
older patients with newly diagnosed AML using zosuquidar
by prolonged infusion with conventionally administered
daunorubicin and cytarabine (E3999) was also ineffective at
improving outcomes (Cripe et al, 2006).
Other investigators have found similar results using the
ciclosporin analogue, PSC-833. In the Cancer and Leukaemia
Group B (CALGB) study of patients over 60 with untreated
AML (CALGB 9720), daunorubicin was given by conventional
bolus infusion along with etoposide and cytarabine in parallel
prospective comparative studies with and without PSC-833
(Baer et al, 2002). Prior to this study, in separate phase I
studies, daunorubicin was dose-adjusted to achieve equivalent
toxicity in those patients receiving PSC-833 to those not
receiving PSC-833. The use of PSC-833 required a 30% dose
reduction of daunorubicin and 40% reduction in etoposide
dose. Despite this dose adjustment, the arm receiving PSC-833
was closed early due to excessive toxicity. Though there were
trends toward improved response and disease-free survival
(DFS) for patients receiving PSC-833, they did not reach
statistical significance. Similar results were seen with patients
younger than 60 years of age in CALGB 9621 (Kolitz et al,
2004). In this set of phase II trials, PSC-833 appeared to
improve DFS and first round induction efficacy, as well as
improve OS in patients younger than 45 years, however,
a confirmatory phase III study (CALGB 19808) was stopped
early when PSC-833 became unavailable (Kolitz et al, 2005).
The Dutch-Belgian Haemato-Oncology Cooperative Group
(HOVON) and MRC performed a parallel prospective com-
parative study with cytarabine and daunorubicin by bolus
infusion at attenuated doses with and without PSC-833, in
patients aged 60 years and over. Patients received two induc-
tion cycles followed by a single cycle without PSC-833 as
consolidation (van der Holt et al, 2005). Again, there was a
trend toward improved DFS for patients who received
Table IV. Effects of MDR1 expression and functional efflux on response to induction chemotherapy, by study.










MRK16 Negative 13 5 (38%) 4 (31%) 21 10 (48%) 3 (14%)
Weak positive 5 4 (80%) 1 (20%) 4 1 (25%) 3 (75%)
Positive 32 10 (31%) 11 (34%) 25 11 (44%) 7 (28%)
Trend* P = 0Æ15 P = 0Æ098 P = 0Æ30 P = 0Æ94
Di(OC)2 efflux Negative 9 6 (67%) 1 (11%) 17 9 (53%) 2 (12%)
Weak positive 1 1 (100%) 0 (0%) 3 1 (33%) 0 (0%)
Positive 27 8 (30%) 11 (41%) 16 6 (38%) 7 (44%)
Not done 13 4 (31%) 4 (31%) 14 6 (43%) 4 (29%)
Trend* P = 0Æ34 P = 0Æ48 P = 0Æ52 P = 0Æ049
Rh123 efflux Negative 8 5 (63%) 2 (25%) 20 12 (60%) 2 (10%)
Weak positive 1 1 (100%) 0 (0%) 3 0 (0%) 1 (33%)
Positive 23 6 (26%) 10 (43%) 13 4 (31%) 6 (46%)
Not done 18 7 (39%) 4 (22%) 14 6 (43%) 4 (29%)
Trend* P = 0Æ036 P = 0Æ54 P = 0Æ49 P = 0Æ12
*Two-sided P-value based on logistic regression, treating MRK16 expression or efflux D-value as a continuous variable, excluding patients with assay
not done.
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PSC-833, though other outcomes were not improved. A later
MRC trial, LRF AML14, showed increased induction mortality
with PSC-833, with no apparent benefit to remission duration.
(Burnett et al, 2009). Similarly, the ECOG performed a
prospective comparative study utilizing PSC-833 along with
conventional bolus infusion of mitoxantrone, etoposide and
cytarabine in patients with relapsed and refractory disease in
E2995 (Greenberg et al, 2004), again without improvement in
any outcome parameters assessed, though PSC-833 decreased
clearance of mitoxantrone and etoposide in predictable
fashion.
SWOG also performed a phase I dose-escalation study
(S9617) using mitoxantrone and etoposide by conventional
bolus administration along with PSC-833 by continuous
infusion, and determined a maximum tolerated dose (MTD)
consistent with other studies in patients with AML over
55 years-old (Chauncey et al, 2000). However, after comple-
tion of the study, the regimen was not further pursued based
on results of S9333, which showed that mitoxantrone and
etoposide regimen given as first-line therapy for older patients
with AML, was not superior to conventional daunorubicin and
cytarabine (Anderson et al, 2002). Of note, in the AML11
prospective comparative trial of three different induction
regimens, the MRC showed that their etoposide-containing
regimen was less effective at achieving remission than the
combination of anthracyclines and cytarabine in older AML
patients (Goldstone et al, 2001).
In contrast, the GOELAMS (Groupe Ouest Est d’Etude des
Leucémies et Autres Maladies du Sang) study in patients with
de novo AML aged between 15 and 60 years old, used quinine
by continuous infusion along with cytarabine by continuous
infusion and idarubicin by conventional bolus administration
(Solary et al, 2003). Patients with persistent disease after this
regimen received high-dose cytarabine and mitoxantrone, and
patients in CR received consolidation with an amsacrine and
cytarabine regimen. After that, patients underwent ablative
allogeneic transplant from a sibling donor or chemotherapy
consolidation with high-dose cytarabine and mitoxantrone
followed by amsacrine and etoposide with and without
quinine. In this study, quinine improved response, EFS and
OS for those patients with demonstrated Rh123 efflux, though
this subgroup analysis did not reach statistical significance for
EFS and OS.
MDR-1 expression may serve as a marker for other
mechanisms of resistance that parallel the induction and/or
selection of MDR-1 expression. In addition to Pgp, other ATP-
binding cassette (ABC)-efflux mediators such as MRP and
BCRP, as well as LRP, correlate with resistance in various
clinical settings, and PSC-833 and ciclosporin may be clinically
less effective at modulating drug-efflux by these other trans-
porters. Because the presence of other transporters was not
assessed in the current study, their significance in this dataset is
unknown.
It is likely that many mutations exist in leukaemia cells in
older patients with AML, as well as redundant mechanisms of
resistance, complicating any therapeutic approach. While the
increased expression of an MDR phenotype in the blasts of
older patients continues to represent a theoretically attractive
target, attempts to reverse that phenotype as a single approach
have not had the anticipated success in this patient population.
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